Abstract: Disclosed in the present invention are a purification method and system of NMMO and a NMMO hydrate crystal obtained thereof. The purification method is suitable for purifying NMMO in a coagulating bath of a cellulose product, and by means of the method, almost all impurities including carbohydrate impurities can be removed from the NMMO solution of the coagulating bath of the cellulose product and a high-purity NMMO hydrate crystal is obtained. The purification method comprises the following steps: performing a cooling crystallization to the coagulating bath of the cellulose product between ?20° C. and 78° C. to obtain NMMO hydrate crystals. According to the method for purifying and recovering NMMO in the coagulating bath of the cellulose product in the invention, ion-exchange resins are not needed, and acid and alkali are not needed for resin regeneration.

Abstract: The invention discloses a purification method and system of N-methylmorpholine N-oxide (NMMO), and a N-methylmorpholine N-oxide obtained thereof. The invention is used for recovering and purifying NMMO in a lyocell fiber coagulation bath. The method comprises: performing flocculation, microfiltration, ultrafiltration and nanofiltration membrane separation process to the lyocell fiber coagulation bath to remove macromolecular impurities such as suspending substance, heavy metal ions, heavy metal complexes, polysaccharides, etc., and then performing cooling crystallization between ?20° C. and 78° C. to obtain NMMO hydrate crystals. The NMMO hydrate crystals obtained by the method provided in the invention do not contain PG, PG oxidation products, cellulose breakdown products, and NMMO decomposition products, which are present in the coagulation bath. The NMMO hydrate crystals are added with water to prepare a NMMO aqueous solution with a concentration of 19.8%, and the electrical conductivity is about 14.

Abstract: The invention discloses a purification method, system and a detection method of N-methylmorpholine N-oxide (NMMO), and a N-methylmorpholine N-oxide obtained thereof. The NMMO is derived from a NMMO crude product prepared by the reaction of N-methylmorpholine with hydrogen peroxide. The mass concentration of NMMO in the NMMO crude product is 50% to 60%. The purification method includes: performing cooling crystallization to the NMMO crude product between ?20° C. and 78° C. to obtain crystalline NMMO. The NMMO purification method has a low cost, a high purity of the obtained NMMO product, and almost no generation of exhaust gas, waste water, and solid waste. Different from current NMMO purification process, the purification method of the invention does not require ion-exchange resin, thus completely solved problems of significant amount of wastewater with high concentration of salt and COD and spent ion-exchange resin caused by the regeneration of ion-exchange resin.

Abstract: Provided herein are recombinant nucleic acid molecules, nucleic acid constructs, fusion enzymes, transformed host cells, and methods for making aroma compounds alpha-ionone or beta-ionone.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present invention provides compounds having formula (I): wherein R?, R0, R1, X1, R2, R3, R3?, X2, X3 and R4 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (?-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by ?-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

Abstract: The present invention provides compounds having formula (I): 1

Abstract: Triphenyl compounds of the formulae I, II, and VI: methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are compounds are interleukin-4 antagonists; and are useful for the treatment of asthma and allergies.